AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Statins have long been a cornerstone of heart disease prevention, working by reducing cholesterol production in the liver.

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

Specifically, a child is three to four times more likely to become an obese adult if their mom was obese, researchers ...

A new study has found that combining statins - the first-line treatment for high cholesterol - and ezetimibe, another drug ...

If it can’t be absorbed, it won’t reach your bloodstream. The only one on the market is the drug ezetimibe, available as a generic or as the name brand Zetia. This drug can be combined with ...

Combining statins with another drug, ezetimibe, significantly reduces the risk of death in patients with clogged arteries, according to findings published Sunday in Mayo Clinic Proceedings.

Researchers explore how natural compounds in traditional Chinese medicine can modulate cholesterol metabolism to combat ...

The drug decreases the LDL-cholesterol (LDL-C ... The combination of orlistat with statins, fenofibrate and ezetimibe led to greater reductions of LDL-C levels compared with each monotherapy.